a leading Germany-based, cGMP compliant biopharmaceutical Contract Development and Manufacturing Organization (CDMO) announced today the start of construction for an expansion project at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biological manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023.
“The market for pharmaceutical biotechnology has been continuously growing and further growth is expected. In order to accommodate demand for high value biopharmaceutical products, Richter-Helm recently started expansion of its microbial manufacturing capacity and continues to push its overall growth strategy.” said Dr. Kai Pohlmeyer, Managing Director at Richter-Helm. The basic engineering of the new facility has been completed and the ground-breaking ceremony took place on May 5th, 2021 by the management team of Richter-Helm, who initiated construction of the new facility.
Richter-Helm and its mother companies Gedeon Richter and HELM AG will invest close to 70 million € to triple the current production capacity and expand its existing warehouse, laboratory, and administration buildings.
Currently, Richter-Helm operates two cGMP-compliant production facilities located in Hannover and Bovenau, Germany, with bioreactor capacities of up to 1,500 litres. The Bovenau expansion covers installment of two additional highly flexible and fully equipped production trains with interchangeable product flows. Bioreactor capacities of 300 litres and 1,500 litres will be added. The production site will reach a total area of about 10,000 m² and includes all necessary utilities and infrastructure, like QC-labs, warehouse and technical areas.
Dr. Kai Pohlmeyer further explains: “With the addition of two new manufacturing trains, Richter-Helm is supporting the demand of its existing customers and the needs of the growing biopharmaceutical market. We will be more flexible and more efficient in bringing products of our worldwide pharmaceutical clients to market. We also expect to create a significant number of new jobs for qualified professionals once the plant becomes fully operational“.
More News
HALRIC Strengthens Life Science Connections in Northern Europe
After three years, Life Science Nord has issued a positive assessment of the Interreg project HALRIC – Hanseatic Life Science Research Infrastructure Consortium. The project’s ...
Read more …
#NEWatLSN: Galagos
We are delighted to welcome Galagos as a new member of Life Science Nord e.V.! The founding team answered questions about the company’s initial goals, ...
Read more …
HALRIC in Brussels
Through direct dialogue with the European Commission and Member States, HALRIC’s Brussels discussions showed how cross-border life science collaboration can unlock efficiency, strengthen European competitiveness, ...
Read more …